Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, trading at neutral
Target Price
The average target price of 2552.HK is 5.9 and suggests 81% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell